Discovery IND-enabling Phase 1 Phase 2 Phase 3 Approved
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-Dependent Cushing's Syndrome
CRN09682, Non-Peptide Drug Conjugate
NETs and SST2-Expressing Tumors
PTH Antagonist
Hyperparathyroidism
TSH Antagonist
Graves' Disease, TED
SST3 Agonist
Polycystic Kidney Disease
SST5 Agonist
Hyperinsulinism
Oral GLP-1 Nonpeptide
Diabetes, Obesity
Oral GIP Nonpeptide
Diabetes, Obesity
Radionetics
Targeted Radiotherapy for Multiple Solid-Tumors
Discovery IND-enabling Phase 1 Phase 2 Phase 3 Approved
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-Dependent Cushing's Syndrome
CRN09682, Non-Peptide Drug Conjugate
NETs and SST2-Expressing Tumors
PTH Antagonist
Hyperparathyroidism
SST3 Agonist
Polycystic Kidney Disease
SST5 Agonist
Hyperinsulinism
TSH Antagonist
Graves' Disease, TED
Oral GLP-1 Nonpeptide
Diabetes, Obesity
Oral GIP Nonpeptide
Diabetes, Obesity
Radionetics
Targeted Radiotherapy for Multiple Solid-Tumors

Paltusotine(oral SST2 agonist)


In development for the treatment of acromegaly, neuroendocrine tumors (NETs) and carcinoid syndrome, our lead product candidate represents a potentially new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist.

atumelnant (CRN04894)(oral ACTH antagonist)


This is the first oral, selective ACTH antagonist in development for the treatment of ACTH-dependent Cushing’s syndrome and other diseases of excess ACTH, such as congenital adrenal hyperplasia (CAH).